| 1 |
Gajbhiye SA, Patil MP. SOLID LIPID NANOPARTICLES: A REVIEW ON DIFFERENT TECHNIQUES AND APPROACHES TO TREAT BREAST CANCER. Int J App Pharm 2023. [DOI: 10.22159/ijap.2023v15i2.46970] [Reference Citation Analysis]
|
| 2 |
Gruzdev DA, Telegina AA, Levit GL, Solovieva OI, Gusel'nikova TY, Razumov IA, Krasnov VP, Charushin VN. Carborane-Containing Folic Acid bis-Amides: Synthesis and In Vitro Evaluation of Novel Promising Agents for Boron Delivery to Tumour Cells. Int J Mol Sci 2022;23. [PMID: 36430206 DOI: 10.3390/ijms232213726] [Reference Citation Analysis]
|
| 3 |
Nahvi I, Belkahla S, Biswas S, Chakraborty S. A Review on Nanocarrier Mediated Treatment and Management of Triple Negative Breast Cancer: A Saudi Arabian Scenario. Front Oncol 2022;12:953865. [DOI: 10.3389/fonc.2022.953865] [Reference Citation Analysis]
|
| 4 |
Wang Z, Li J, Lin G, He Z, Wang Y. Metal complex-based liposomes: Applications and prospects in cancer diagnostics and therapeutics. J Control Release 2022;348:1066-88. [PMID: 35718211 DOI: 10.1016/j.jconrel.2022.06.012] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 5 |
Rahim MA, Madni A, Tahir N, Jan N, Shah H, Khan S, Ullah R, Bari A, Khan MS. Mild Hyperthermia Responsive Liposomes for Enhanced In Vitro and In Vivo Anticancer Efficacy of Doxorubicin against Hepatocellular Carcinoma. Pharmaceutics 2021;13:1310. [PMID: 34452271 DOI: 10.3390/pharmaceutics13081310] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 6 |
Iqbal Z, Arafa EA, Kanwal Z, Murtaza G. Smart solution of severe problems: Radiolabeled nanocarriers for cancer imaging and therapy. Journal of Drug Delivery Science and Technology 2021;61:102205. [DOI: 10.1016/j.jddst.2020.102205] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 7 |
Gabizon AA, de Rosales RTM, La-Beck NM. Translational considerations in nanomedicine: The oncology perspective. Adv Drug Deliv Rev 2020;158:140-57. [PMID: 32526450 DOI: 10.1016/j.addr.2020.05.012] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 5.7] [Reference Citation Analysis]
|
| 8 |
Böttger R, Pauli G, Chao PH, Al Fayez N, Hohenwarter L, Li SD. Lipid-based nanoparticle technologies for liver targeting. Adv Drug Deliv Rev 2020;154-155:79-101. [PMID: 32574575 DOI: 10.1016/j.addr.2020.06.017] [Cited by in Crossref: 34] [Cited by in F6Publishing: 39] [Article Influence: 11.3] [Reference Citation Analysis]
|
| 9 |
Fu Y, Rathod D, Abo-Ali EM, Dukhande VV, Patel K. EphA2-Receptor Targeted PEGylated Nanoliposomes for the Treatment of BRAFV600E Mutated Parent- and Vemurafenib-Resistant Melanoma. Pharmaceutics 2019;11:E504. [PMID: 31581483 DOI: 10.3390/pharmaceutics11100504] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 10 |
Al-Hatamleh MAI, Ahmad S, Boer JC, Lim J, Chen X, Plebanski M, Mohamud R. A Perspective Review on the Role of Nanomedicine in the Modulation of TNF-TNFR2 Axis in Breast Cancer Immunotherapy. J Oncol 2019;2019:6313242. [PMID: 31239840 DOI: 10.1155/2019/6313242] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 4.5] [Reference Citation Analysis]
|
| 11 |
Man F, Gawne PJ, T M de Rosales R. Nuclear imaging of liposomal drug delivery systems: A critical review of radiolabelling methods and applications in nanomedicine. Adv Drug Deliv Rev 2019;143:134-60. [PMID: 31170428 DOI: 10.1016/j.addr.2019.05.012] [Cited by in Crossref: 55] [Cited by in F6Publishing: 52] [Article Influence: 13.8] [Reference Citation Analysis]
|
